anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
This study is a prospective observational cohort study aimed at thoroughly investigating the disease progression and influencing factors of patients with moderate aortic valve disease, diagnosed at the Second Affiliated Hospital of Zhejiang University School of Medicine. Aortic valve stenosis and aortic regurgitation are the most common forms of aortic valve disease. According to the 2021 ESC guidelines, moderate aortic stenosis (Moderate AS) is defined as an aortic valve area (AVA) of 1.0-1.5 cm2 on echocardiography (or AVA \&lt;1.0 cm2 with an AVA index of 0.60-0.85 cm2/m2), a peak jet velocity (Vmax) of 3-4 m/s, and/or a mean transvalvular gradient (MG) of 20-40 mmHg. Moderate aortic regurgitation (Moderate AR) is defined as a regurgitant fraction between 30% and 50% or an effective regurgitant orifice area between 0.10-0.30 cm2.

While treatment guidelines for patients with severe AS are well-established, there is currently no clear consensus on the treatment of patients with moderate AS, and the subsequent disease progression for these patients remains unclear. Similarly, when the aortic valve shows only moderate regurgitation, surgical treatment is usually not required; the most important aspect is regular monitoring of disease changes, including regular echocardiographic examinations. It is noteworthy that the time span from moderate to severe aortic regurgitation can vary from 1 to 10 years, and the monitoring and early warning mechanisms for potential markers indicating disease deterioration are currently not well developed. The goal of this study is to identify all clinical characterization, biological, echocardiographic, and CT imaging parameters that may increase the risk of disease progression. The confirmation of these parameters will guide future research to develop medical and interventional treatment methods to reduce mortality associated with this disease. Patients participating in this study will undergo outpatient follow-up every 1 year after diagnosis and will undergo electrocardiography, echocardiography, blood analysis, and enhanced CT examinations at 1, 3, and 5 years (plus once if an endpoint event occurs). Through these comprehensive monitoring methods, we expect to more accurately assess changes in the patient\&#39;s condition and provide a scientific basis for clinical decision-making.
PURPOSE:To obtain the title material suitable for such medical products as to be in contact with the blood for a long period of time by introducing tertiary amino group into the side chain of a PVA-based polymer followed by mixing with heparin in its solution state and then forming into a hydrogel. CONSTITUTION:A compound having in the molecule both tertiary amino and aldehyde groups (e.g. p-dimethylaminobenzaldehyde) is reacted with a PVA-based polymer to prepare a solution of a PVA-based polymer with tertiary amino group in its side chain. Heparin is then added to this solution followed by neutralization with pref. an alkali to adjust the pH of the solution to &gt;=2. Thence, the resulting solution is either formed or applied on the surface of a base material followed by solidification into a hydrogel, thus giving the objective heparin sustained release material. With this method, the present material with a large amount of heparin carried within can be obtained. Formation of ionic bond in the present material will result in the slower release of the heparin, thus maintaining anti-thrombogenicity for a long period of time.
FIELD: medicine, urology. SUBSTANCE: etiotropic therapy is carried out by administration of pyobacteriophage and pathogenetic therapy involves carrying out microenemas with electroactivated aqueous solution of Zn, Mg and Mn salts prepared in apparatus &#34;Espero-1&#34;. The first two days therapy is carried out with anolyte and for the following 5-7 days - with catholyte of the indicated solutions and by addition of dimexide (4 ml/100 ml solution). Method ensures to arrest the pain syndrome for short times. Method can be used for treatment of patients with chronic inflammatory prostate sicknesses. EFFECT: enhanced effectiveness of treatment. 1 tbl, 2 ex
PURPOSE:To obtain a powdery preparation produced by forming a syrup containing galactooligosaccharide with zeolite in the form of pharmaceutical preparation, producible at a low cost and having easy handleability in the compounding of the preparation to a feed. CONSTITUTION:The objective preparation is composed of (A) a syrup containing galactooligosaccharide and (B) a zeolite (preferably mordenite-type zeolite). The preparation is preferably produced by kneading and granulating the components A and B with a high-speed agitation mixing granulator, a kneader, etc., and, as necessary, subjecting the obtained granules to coarse crushing, sieving and drying. The component A preferably has a solid concentration of &gt;=75% in the syrup and a galactooligosaccharide concentration of &gt;=50% in the solid component. The galactooligosaccharide is e.g. 6-galactosyl lactose produced by treating lactose with beta-galactosidase.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide domains and epitopes of meningococcal protein NMB 1870.  &lt;P&gt;SOLUTION: The NMB 1870 is a known surface protein in Neisseria meningitidis expressed across all serogroups, and has three distinct families. Serum raised against a given family is bactericidal within the same family, but is not active against strains which express one of the other two families i.e. intra-family but not inter-family cross-protection. The followings are found out: the NMB 1870 can be divided into domains wherein not all the domains are required for antigenicity. The antigenic domains can be taken from each of the three NMB 1870 families and expressed as a single polypeptide chain.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
PURPOSE:To provide a clear cosmetic containing a polyhydric alcohol having &gt;=2 OH groups in the molecule, water, an amino acid-base hydrophilic surfactant and a liquid oil, having high transparency, broad transparent region and high safety and giving good feeling to the skin. CONSTITUTION:The objective clear cosmetic contains (A) a polyhydric alcohol having &gt;=2 hydroxyl groups in the molecule (especially preferably glycerol, sorbitol, etc.), (B) water, (C) an amino acid-base hydrophilic surfactant (e.g. hardened castor oil pyroglutamic acid isostearic acid diester, etc., having HLB of &gt;=9) and (D) a liquid oil (e.g. 2-ethylhexanoic acid triglyceride, olive oil, etc.) in combination. The cosmetic can be extremely easily produced and keeps excellent transparency over a broad temperature range even after long-term storage. It has high safety and gives excellent feeling to the skin.
Systems and methods are provided for identifying characteristics of a subject using a biofield scan obtained from the subject. An embodiment can include a method for cross-correlating biofield scans to an enome database, and/or a genome database. A phenotype history and a biofield scan can be created from a user. A user&#39;s biofield scan can be created from measured amplitude and frequency. A database is created from a user&#39;s phenotype history, and biofield scan. The user&#39;s phenotype history and biofield scans are then correlated with known physical and biochemical characteristics. A biofield signature is created and compared to the user&#39;s phenotype history, and biofield scan.
Generally described, the present disclosure relates to medical information and more particularly, to a system for migrating personal health information and methods thereof. In an illustrative embodiment, the migration platform can include an importation and reconciliation module, migration form and exportation module. The importation module can load the migration platform with known information from a source system. In turn, the reconciliation module can determine what elements can be automatically transferred to the target system and which elements to apply migration business rules to. A migration technician can convert elements which cannot be automatically migrated. The migration form can break down and group the patient&#39;s chart into sections and elements for review by the technician. The migration form can also display the elements in an easy-to-follow format and manage pairs of information. The exportation module of the migration platform can take the completed chart, after review, and populate the target system.
The invention discloses a sandwich outer membrane protein display vector and an escherichia coli vaccine prepared by applying the same. The invention provides two fusion proteins which are fusion protein A or fusion protein B. The fusion protein A comprises the following segments from the N-end to the C-end sequentially: a segment A consisting of amino acid residues at first to 136&lt;th&gt; positions from the N tail end of a sequence 2 in a sequence table; a segment B consisting of amino acid residues at 512&lt;th&gt; to 634&lt;th&gt; positions from the N tail end of the sequence 2 in the sequence table; and a segment C consisting of amino acid residues at 635&lt;th&gt; to 726&lt;th&gt; positions of the sequence 2 in the sequence table. The fusion protein B is obtained by inserting a heterologous protein between the segment A and the segment B of the fusion protein A. When encoding genes of the fusion proteins disclosed by the invention are inducted into bacteria, recombinant bacteria can be obtained. A ghost of the recombinant bacteria can be used as the bacterial vaccine. The bacterial vaccine does not contain a genome of the bacteria, but contains the fusion proteins, is safe and has excellent effect.
PURPOSE:To obtain a lyophilized preparation of dissolution type in use, suitable for preparing an injection by dissolving the preparation in a solvent, containing a specific cephem-based antibiotic and an inorganic salt. CONSTITUTION:A compound shown by the formula (R is lower alkyl; Y is 5-membered heterocyclic ring selected from pyrazolyl, imidazolyl, 1,2,4-triazolyl, oxazolyl or 1,3,4-oxadiazolyl) or a salt thereof and an inorganic salt (e.g. sodium chloride) are used. Further the compound and the salt are mixed with a saccharide (e.g. mannitol), dissolved in water and lyophilized by a conventional procedure to give the objective substance. The amount of the inorganic salt added is &gt;=100mg based on 1g compound shown by the formula and that of the saccharide is &gt;=20mg. A cephem-based antibiotic preparation which is only added and dissolved in an injection solution in use even after long-term preservation, has excellent solubility, excellent stability of the compound shown by the formula, slight change of color and has excellent stability in storage.
PURPOSE:To obtain a plaster having balanced transcutaneous absorbability of drug and skin irritation and suitable for repeated application to the same part of the skin by using a plaster layer composed of a specific composition and a tacky adhesive material consisting of a polymeric substance having carboxyl group. CONSTITUTION:The objective plaster can be prepared by compounding (A) a fatty acid glycerol ester (e.g. glycerol monooleate) and (B) an alkali metal hydroxide to (C) a tacky adhesive agent consisting of a polymeric substance having carboxyl group, preferably and acrylic polymer containing &gt;= 50 wt.% of (meth)acrylic acid ester having alkyl groups having an average C number of &gt;= 4 and copolymerized with a copolymerizable functional monomer and laminating the obtained plaster layer to a flexible substrate. Preferably, the thickness of the plaster layer is 10-100mum and that of the substrate is 5-150mum. When a drug is compounded to the plaster, the drug can be stably held in the plaster to prevent the decrease of the drug content. Excellent effect can be attained especially in the case of using a drug having carboxyl group.
PURPOSE:To recover a proteinic substance by a highly separating, purifying and concentrating the proteinic substance, by adsorbing the substance in a specific ion exchanger, and eluting the proteinic substance with an eluent. CONSTITUTION:A solution containing a proteinic substance is adsorbed in an ion exchanger. In the process, synthetic ion exchange fibers, e.g. synthetic organic ion exchange fibers obtained by introducing ion exchange groups into a synthetic organic polymer, e.g., polystyrene, having &gt;=1.0 moisture content. After the adsorption, the proteinic substance is then eluted with an eluent, e.g a salt such as NaCl or KCl, and recovered. The fibers are brought into contact by the batch, fixed bed methods, etc., preferably the fixed bed method. EFFECT:The fibers used as the ion exchanger can be adopted in an optional form, and the recovering operation can be easily repeated several times. The resistance to solution passage is low.
System, methods and electronic devices aimed at motivating users to perform physical activity are disclosed herein. A user may be presented with a series of physical and cognitive exercises. For example, an exercise may be locked until completion of an unlocked exercise. Performance in each exercise may be tracked to display feedback to a user and track the user&#39;s improvement over time. Physical exercises may comprise challenges to move a particular distance or take a particular number of steps. Cognitive exercises comprise techniques test or train the cognitive abilities of the user in: attention, memory, processing speed, logical reasoning, numerical reasoning, spatial reasoning, verbal reasoning, language, and cognitive executive functions. Performance in one exercise may modify the difficulty or parameters of a subsequent exercise. The tracking of user improvement may comprise a progress or reward system such as the increasing of a user&#39;s “level” or awarding of “badges.”
PROBLEM TO BE SOLVED: To obtain a massage cosmetic having excellent immunopotentiating actions by using a specific wax with a specified hydroxy-fatty acid in combination. SOLUTION: This immunopotentiating massage cosmetic is obtained by combining a high-melting wax with a 12-22C hydroxy-fatty acid. The content of an ingredient which is a solid at normal temperatures other than the high- melting wax and the 12-22C hydroxy-fatty acid is preferably 1-15wt.% in the massage cosmetic. A high-melting wax having &gt;=60 and &lt;=110 deg.C melting point is preferred as the high-melting wax and carnauba wax, Japan wax, spermaceti, beeswax, etc., are especially cited. A hydroxy-stearic acid is preferred as the hydroxy-fatty acid. The content of the high-melting wax is 5-20wt.% and that of the fatty acid is 0.1-5wt.%. The dosage form is preferably an oil gel one.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method for treating diabetes.  &lt;P&gt;SOLUTION: A gene INGAP exhibits remarkable homology with a gene of a PAP (pancreatitis associated protein) family. The cDNA sequence of a mammalian INGAP and a predicted amino acid sequence are provided in specific sequences and a pharmaceutical composition comprises the INGAP protein. The predicted protein shares a CRD (carbohydrate recognition domain) of a calcium-dependent C-type lectin. The INGAP protein plays a role in stimulation of pancreatic islet neogenesis, particularly β-cell regeneration from pancreatic duct cells.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To make expensive special medicines and the treatment by doctors unnecessary, which have been conventionally required for therapy of tooth gum swelling, pyorrhoea alveolaris, decayed tooth, halitosis, stomatitis, lingual cancer, throat cancer, common cold and the like.  &lt;P&gt;SOLUTION: The prevention and therapy can be performed by each individual in his home, easily, simply and at a low cost. A liquid obtained by mixing a liquid (1) corresponding to water, a liquid (2) containing salt or a salinity component, and, in some cases, a halitosis preventive (5), is prepared. In the liquid, chlorine ion and sodium ion coexist in the state that they are enclosed with hydrogen and oxygen of water molecules, and separated. The chlorine ion enclosed with hydrogen of the water molecule has germicidal action. And, when coming into contact with someone, good smell is generated by action of the halitosis preventive (5), so that good impression is presented to him. By using the liquid, the teeth are polished and the mouth is washed and gargled, directly.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
(-)-(S)-3-(3&#39;-hydroxy)-butylphthalide (a compound shown by Formula I) and an ester formed of the same and an acid are proved by experiments to be applicable to treatment and prevention of cerebral ischemic diseases and have a sleep-improving function. The acid refers to a pharmaceutically acceptable inorganic or organic acid. The inorganic acid refers to nitric acid, sulfuric acid, or phosphoric acid. In addition to an acid radical, the organic acid at least comprises at least one of an amino group, a hydroxyl group, and a carboxyl group. None of the compound shown by Formula I and the ester thereof is water-soluble. An ester generated from the compound and the acid further react with an acid or a base to generate a salt which is water-soluble and is used to prepare injection preparation. The experiment proves that the salt does not stimulate vessels.
20130100118 Novelty: an autologous dentric genetically-modified cell vaccine for fighting human cancer tumours is disclosed. Composition: the invented vaccine is composed of active genetically-modified autologous human dentric cells. The cells of the human immune system are actuated by fusion of the first with the cytasol of the patient’s tumour. The human recombined genes of the present invention have specific action mechanism aiming at the increase of the anti-cancer activity, of the specificity of the targeting of the cancer cells and of the maturation rhythm of the autologous dentric cells derived from the isolated fraction of the patient’s monocellular peripheral blood. The autologous dentric cells of the present invention can be genetically modified and superinfected by the following recombined genes (microRNAs &lt; hsa-mir-34a ΜΙ0000268 &lt; hsa-mir-146a ΜI0000477 &lt; hsa-mir-155 ΜI0000681 &lt; hsa-mir-221 ΜI0000298 &lt; hsa-mir-222 MI0000299 &lt; hsa-mir-146a ΜI0000477 &lt; hsa-miR-146a-5p MIMAT0000449 &lt; hsa-miR-146a-3p ΜIΜΑΤ0004608 &lt; hsa-let-7i ΜI0000434 &lt; hsa-let-7i-5p MIMAT0000415 &lt; hsa-let-7i-3p MIMAT0004585 hisa-mir-2J MI0000077) and the preserved regions of specific sequences of the nucleotic bases thereof with the aim to increase the anti-cancer action and the capability of targeting the cancer cells of the patient. Purpose: composition of a pharmaceutical preparation on a uniform acceptable compatible vector carrying the present autologous dentric and genetically-modified vaccine for the vaccination of patients suffering from cancer tumours.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a rapid release particle comprising zolpidem tartrate as an active ingredient and having masked unpleasant bitterness of the drug.  &lt;P&gt;SOLUTION: The rapid release particle is prepared by coating a core containing the zolpidem tartrate as the active ingredient with a film containing ethyl cellulose and a water-soluble polymer. In the rapid release particle, the content of the ethyl cellulose accounts for 60-75 wt.% of the film and the diameter of the particle is ≤250 μm. Thereby, the particle which has the masked unpleasant bitterness of the drug without unpleasant sandiness and can be contained in an easily administrable pharmaceutical preparation such as a disintegrating tablet in the oral cavity, a jelly or a film administrable without water is obtained. The particle without unpleasant sandiness can be incorporated in the easily administrable pharmaceutical preparation such as the disintegrating tablet in the oral cavity, jelly or film administrable without water.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
PURPOSE:To obtain a skin cleaning and wiping agent composition having a high cleaning effect and excellent using feeling containing water-insoluble powder having a specific granular diameter. CONSTITUTION:1-20wt.% powder substantially insoluble in water having &lt;=100mum granular diameter, e.g. titanium oxide, talc or kaolin, is contained in an oily component (e.g. squalane). Furthermore, 10-40wt.% water and a water-soluble solvent (e.g. lower alcohol) is mixed therewith. Then, suitable amounts of emulsifier, sterilizer, antiphlogistic, flavor or dyestuff, etc., are mixed, as necessary, to afford the objective material. Said material can be prepared to an aerosol formulation or a pump-type spraying agent. The agent is used by spraying or applying on toilet paper, etc., and after defecation, excrement is wiped out by usual toilet paper, etc., then excrement remaining on the circumanal part of anus is removed by the agent-sprayed paper. Thereby, damage of skin by friction and pain in wiping are reduced and hemorrhoids, a rash and itch, etc., on the circumanal part are prevented.
FIELD: medicine, oncology. SUBSTANCE: the present innovation deals with treating senile patients above 60 with non-Hodgkin&#39;s lymphomas of II-IV stages with massive lesion of abdominal and inguinal-femoral lymph nodes. It is suggested to inject the mixture of antitumor preparations into lymph node at rear part of patient&#39;s foot on the 1st and 8th d of therapy course at single dosages at the following composition: cyclophosphan 1200 mg, metotrexate 150 mg, and then, in turn, at the same days: prednisolon 60 mg and highly purified recombinant interferon-alpha2b - Intron A at single dosage of 9×10 6  IU; in 2-3 wk after physical and instrumental monitoring at partial regression of tumor or stabilization of process one should conduct repeated courses of endolymphatic polychemotherapy with interferon-alpha2b, if necessary, treatment should be supplemented with radiation therapy. The present innovation helps to decrease tumor size, inhibit disease progressing and improve life quality. EFFECT: higher efficiency of therapy. 1 ex
In some examples, a patient care pathway is coupled with a cytokine release syndrome (CRS) prediction system. A CRS prediction machine learning model is used to analyze patient-related health data associated with a monitored user, such as a patient. The health data includes physiological data obtained from sensor devices associated with the monitored patient and user-provided data associated with the monitored patient. A CRS event prediction indicates the probability of an occurrence of a CRS event within a time-period after the prediction is generated. A CRS event that is predicted or detected in progress is graded to indicate a predicted severity. An outcome can also be generated indicating whether the patient&#39;s condition is predicted to improve within the future time-period, enabling more accurate early detection of CRS events for improved patient outcomes. In some examples, the prediction can facilitate a patient care pathway for improved, safer, and more cost-effective care.
Point mutations of the NADP + -dependent isocitrate dehydrogenases (IDH1 and IDH2) occur early in the pathogenesis of gliomas. When mutated, IDH1 and IDH2 gain the ability to produce the metabolite (R)-2-hydroxyglutarate (2HG), but the downstream effects of mutant IDH1 and IDH2 proteins or of 2HG on cellular metabolism are unknown. Here, we profiled &gt;200 metabolites in human oligodendroglioma cell line (HOG) cells to determine the effects of expression of IDH1 and IDH2 mutants. Levels of amino acids, glutathione metabolites, choline derivatives, and tricarboxylic acid (TCA) cycle intermediates were altered in both mutant IDH1- and IDH2-expressing cells. These changes were similar to those identified after treatment of the cells with 2HG. Remarkably, N-acetyl-aspartyl-glutamate (NAAG), a common dipeptide in brain, was 50-fold reduced in cells expressing IDH1 mutants and 8.3-fold reduced in cells expressing IDH2 mutants. NAAG was also significantly lower in human glioma tissues containing IDH mutations than in gliomas without such mutations.